BIOARRAY is a genomics-based diagnostics company focused on fundamentally changing the paradigm of cancer treatment.
One of the leading issues in healthcare today is avoiding over treatment and determining the optimal treatment plan for early-stage cancers. BIOARRAY’s proprietary panel of unique genes is the foundation for the development of predictive tests that provide clinically actionable results to guide treatment decisions.
Identifying relevant treatment options upfront means avoiding harmful side effects from ineffective treatment with the opportunity to improve outcomes.
BIOARRAY’s predictive tests are designed to transform cancer treatment management, improve patient quality of life and survival outcomes, as well as reduce healthcare costs associated with unnecessary treatment.